Alloy Therapeutics (alloytx.com) is a biotech startup that provides drug discovery services and technology platforms to the broader scientific community. The company operates in the biologics discovery market, serving small and medium-sized biotech firms. Its business model is centered around democratizing access to advanced biologics discovery services and technology platforms, which it offers through bespoke campaigns or licensing agreements.

Alloy Therapeutics' primary revenue source is from the licensing of its technology platforms and the provision of its discovery services. The company is committed to reinvesting all of its revenue back into innovation, which allows it to continuously develop and acquire new technologies to enhance its offerings and make its clients more successful.

The company's offerings include the ATX-Gx™ Transgenic Mice Platform and the Keyway™ TCR Discovery, among others. These platforms are designed to help clients discover the best therapeutic antibodies for their specific therapeutic targets. In addition to antibodies, Alloy Therapeutics has expanded into adjacent biologic modalities, including genetic medicines, cell therapies, peptides, and delivery, to help its partners find the best therapeutics for diseases, regardless of format.

In summary, Alloy Therapeutics is a biotech startup that offers cutting-edge biologics discovery services and technology platforms to small and medium-sized biotech firms, with a commitment to continuous innovation and client success.

Keywords: Biotech Startup, Drug Discovery Services, Technology Platforms, Biologics Discovery, Licensing, Innovation, Therapeutic Antibodies, Genetic Medicines, Cell Therapies, Peptides.